tetano
Editor, Senior Moderator
Radiol Case Rep
. 2023 Dec 15;19(3):855-858.
doi: 10.1016/j.radcr.2023.11.044. eCollection 2024 Mar. Early-onset herpes simplex encephalitis type 1 triggered by COVID-19 disease: A case report
Kai Inoue[SUP] 1 [/SUP], Hanako Aoki[SUP] 1 [/SUP], Shuta Toru[SUP] 1 [/SUP], Yu Hatano[SUP] 2 [/SUP], Reina Imase[SUP] 2 [/SUP], Hiroshi Takasaki[SUP] 2 [/SUP], Michiko Tanaka[SUP] 2 [/SUP], Saori Adachi[SUP] 1 [/SUP], Hiroaki Yokote[SUP] 1 [/SUP], Hideki Akiyama[SUP] 2 [/SUP], Michio Yamane[SUP] 2 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) causes a systemic inflammatory response and a temporary immunosuppression of hosts. Several reports have showed that reactivation of herpes simplex virus type 1 (HSV-1) is strongly associated with COVID-19. We present a case of a 66-year-old female, who developed HSV-1 encephalitis, showing impaired consciousness and typical MRI findings such as hyperintense lesions in the temporal lobe, insular cortices, bilateral medial frontal lobe on diffusion-weighted imaging, 7 days after the onset of COVID-19 symptoms. The number of cases of encephalitis in patients with COVID-19 is increasing. However, there has been limited reports of HSV-1 encephalitis following COVID-19, especially for cases with an interval of 7 days or less from the onset of COVID-19 symptoms to the onset of HSV-1 encephalitis. Our case highlights the importance of considering HSV-1 encephalitis in the differential when managing a patient with COVID-19-associated neurologic complications, even if it is in the early stages of COVID-19.
Keywords: Acyclovir; COVID-19; HSV-1 encephalitis; Reactivation; Vidarabine.
. 2023 Dec 15;19(3):855-858.
doi: 10.1016/j.radcr.2023.11.044. eCollection 2024 Mar. Early-onset herpes simplex encephalitis type 1 triggered by COVID-19 disease: A case report
Kai Inoue[SUP] 1 [/SUP], Hanako Aoki[SUP] 1 [/SUP], Shuta Toru[SUP] 1 [/SUP], Yu Hatano[SUP] 2 [/SUP], Reina Imase[SUP] 2 [/SUP], Hiroshi Takasaki[SUP] 2 [/SUP], Michiko Tanaka[SUP] 2 [/SUP], Saori Adachi[SUP] 1 [/SUP], Hiroaki Yokote[SUP] 1 [/SUP], Hideki Akiyama[SUP] 2 [/SUP], Michio Yamane[SUP] 2 [/SUP]
Affiliations
- PMID: 38188949
- PMCID: PMC10770472
- DOI: 10.1016/j.radcr.2023.11.044
Coronavirus disease 2019 (COVID-19) causes a systemic inflammatory response and a temporary immunosuppression of hosts. Several reports have showed that reactivation of herpes simplex virus type 1 (HSV-1) is strongly associated with COVID-19. We present a case of a 66-year-old female, who developed HSV-1 encephalitis, showing impaired consciousness and typical MRI findings such as hyperintense lesions in the temporal lobe, insular cortices, bilateral medial frontal lobe on diffusion-weighted imaging, 7 days after the onset of COVID-19 symptoms. The number of cases of encephalitis in patients with COVID-19 is increasing. However, there has been limited reports of HSV-1 encephalitis following COVID-19, especially for cases with an interval of 7 days or less from the onset of COVID-19 symptoms to the onset of HSV-1 encephalitis. Our case highlights the importance of considering HSV-1 encephalitis in the differential when managing a patient with COVID-19-associated neurologic complications, even if it is in the early stages of COVID-19.
Keywords: Acyclovir; COVID-19; HSV-1 encephalitis; Reactivation; Vidarabine.
